Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedIPD (Individual Participant Data) data-sharing plan added and related terminology updated. Study Protocol and Statistical Analysis Plan are now linked, and MeSH terms and record history metadata expanded to improve indexing and transparency of the trial record.SummaryDifference78%

- Check9 days agoChange DetectedA new revision tag (Revision: v3.6.4) is shown, and several non-core study documents/listings were removed from the study record, reflecting a documentation cleanup on the page.SummaryDifference21%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision has been updated from v3.6.2 to v3.6.3, reflecting a newer version of the page content. The change does not modify displayed study information.SummaryDifference0.0%

- Check38 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a minor update to the study documents or page metadata.SummaryDifference0.0%

- Check52 days agoChange DetectedRecruitment status on the study page has been updated to indicate that no participants are being sought. New help/guide sections (How to Read a Study Record, Common Questions, How to Join a Study) were added, and the Intervention/Treatment label was adjusted along with a revision notice (Revision: v3.6.0).SummaryDifference0.4%

- Check59 days agoChange DetectedThe revision label now shows v3.5.5, replacing the previous v3.5.4. This signals that the page has been updated to a newer version.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.